Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study

Table 3

Median BCVA change during the follow-up and proportion of eyes with BCVA improvement ≥2 ETDRS lines, stable BCVA (change < 2 ETDRS lines), and BCVA decrease ≥2 ETDRS lines.

Median (range) BCVA value (logMAR)
	Treatment group		Control group		Comparison between groups
Screening	0.82 (0.30–1.62)	—	0.4 (0.32–0.70)	—
15 days	0.92 (0.24–1.54)		0.46 (0.34–0.82)
1 month	0.82 (0.40–1.30)		0.40 (0.40–0.66)
2 months	0.86 (0.48–1.32)		0.48 (0.40–0.72)
3 months	0.90 (0.44–1.34)		0.54 (0.38–0.68)
6 months	0.92 (0.6–1.54)		0.7 (0.7–0.84)
BCVA change (6 months)	Eyes (%)		Eyes (%)
BCVA improved (≥2 ETDRS lines)	9.1		0
BCVA stable (change <2 ETDRS lines)	72.7		60
BCVA worsened (≥2 ETDRS lines)	18.2		40